9 results on '"Flanagan, Jeremy P. M."'
Search Results
2. Seventeen years of bird‐related eye injuries at the Royal Victorian Eye and Ear Hospital, Melbourne, 2006–2022.
- Author
-
Flanagan, Jeremy P. M., Moyes, Melissa, Goodwin, Todd, Crock, Carmel, and Campbell, Thomas G.
- Published
- 2024
- Full Text
- View/download PDF
3. Quantifying the effect of eccentric ruthenium plaque placement on tumor volume dose.
- Author
-
Flanagan, Jeremy P. M., Udovenya, William H. F., Astrahan, Melvin A., McKay, Daniel, Phillips, Claire, McKenzie, John D., O'Day, Roderick, and Fog, Lotte S.
- Subjects
- *
UVEA cancer , *ATHEROSCLEROTIC plaque , *RUTHENIUM , *DRUG dosage , *RADIATION measurements , *TUMORS , *RADIATION doses - Abstract
Purpose: Ruthenium-106 brachytherapy is a common treatment for small to medium-sized uveal melanomas. In certain clinical contexts, plaques may be placed eccentrically to tumor center. The effect of plaque decentration, a common radiation dose measurement in radiotherapy: D98%, the percentage of the tumor volume receiving at least 98% of the prescribed dose (a commonly used term in radiation oncology), is unknown. We investigated this using two commonly used plaques (CCA and CCB; Eckert & Ziegler, BEBIG GmbH) in silico. Material and methods: Using a Plaque Simulator™ (Eye Physics) plaque modelling software, treatment time required to deliver 100 Gy D98% with central plaque placement was calculated for both plaque models, treating tumors with basal dimensions of 10 mm (CCB plaque only) and 7 mm (CCA and CCB plaques), and a range of thicknesses. D98% was calculated for plaque-tumor edge distances of 0-5 mm. Additionally, we defined minimum plaque-tumor edge distances, at which D98% fell by 10% and 5% (safety margins). Results: D98% decreased as plaque-tumor edge distance decreased, i.e. as plaque eccentricity increased. Minor (< 1 mm) plaque decentration caused minimal D98% changes across tumor thicknesses. Safety margins did not follow a consistent pattern. Conclusions: Eccentric plaque placement reduces the radiation dose delivered to choroidal tumors. Both tumor (thickness, diameter) and plaque (size, location) characteristics are important D98% modulators. Further investigation of the effect of these characteristics and dose to organs at risk is essential. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. A pilot study of the pharmacokinetics of continuous magnesium infusion in critically ill patients.
- Author
-
Jian Wen Chan, Fumitaka Yanase, See, Emily, McCue, Claire, Zhen-Ti Yong, Talbot, Lachlan J., Flanagan, Jeremy P. M., and Eastwood, Glenn M.
- Published
- 2022
- Full Text
- View/download PDF
5. Reduced alcohol-seeking in male offspring of sires exposed to alcohol self-administration followed by punishment-imposed abstinence
- Author
-
Campbell, Erin J., primary, Flanagan, Jeremy P. M., additional, Marchant, Nathan J., additional, and Lawrence, Andrew J., additional
- Published
- 2018
- Full Text
- View/download PDF
6. Anterior Insular Cortex is Critical for the Propensity to Relapse Following Punishment-Imposed Abstinence of Alcohol Seeking.
- Author
-
Campbell, Erin J., Flanagan, Jeremy P. M., Walker, Leigh C., Hill, Mitchell K. R. I., Marchant, Nathan J., and Lawrence, Andrew J.
- Subjects
- *
INSULAR cortex , *TEMPERANCE , *PUNISHMENT (Psychology) , *ANIMAL models of alcoholism , *ALCOHOLISM relapse , *ALCOHOLISM , *GABA agonists - Abstract
Humans with alcohol use disorder typically abstain because of the negative consequences associated with excessive drinking, and exposure to contexts previously associated with alcohol use can trigger relapse. We used a rat model that captures a characteristic of this human condition: namely voluntary abstinence from alcohol use because of contingent punishment. There is substantial variability in the propensity to relapse following extended periods of abstinence, and this is a critical feature preventing the successful treatment of alcohol use disorder. Here we examined relapse following acute or prolonged abstinence. In male alcohol preferring P rats, we found an increased propensity to relapse in Context B, the punishment context after prolonged abstinence. Next, we found that neither alcohol intake history nor the motivational strength of alcohol predicted the propensity to relapse. We next examined the putative circuitry of context-induced relapse to alcohol seeking following prolonged abstinence using Fos as a marker of neuronal activation. The anterior insular cortex (AI) was the only brain region examined where Fos expression correlated with alcohol seeking behavior in Context B after prolonged abstinence. Finally, we used local infusion of GABAa and GABA,, receptor agonists (muscimol + baclofen) to show a causal role of the AI in context-induced relapse in Context B, the punishment context after prolonged abstinence. Our results show that there is substantial individual variability in the propensity to relapse in the punishmentassociated context after prolonged abstinence, and this is mediated by activity in the AI. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Apical dose versus volume dose of Ruthenium-106 brachytherapy for uveal melanoma.
- Author
-
Flanagan JPM, Fog LS, Astrahan MA, Talbot LJ, McKay D, Phillips C, McKenzie JD, and O'Day R
- Abstract
Objective: Ruthenium-106 brachytherapy is commonly used to treat uveal melanomas. Most centres prescribe a radiation dose to the tumour apex that is calculated with the tumour located in the centre of the plaque. Recent work suggests that D
99% -the minimum radiation dose delivered to 99% of tumour volume-may be a better predictor of tumour control than apex dose. Both dosing regimens may be affected by tumour and treatment variables differently. We explored the effect of differences in these variables on volume and apex dose using a 3-dimensional planning model., Methods: The time required to deliver 100 Gy to the tumour apices of representative tumours ranging from 2- to 6-mm thickness with central plaque positioning was calculated in Plaque Simulator™. This treatment time was used for further calculations, including D99% with central plaque placement, and apical and tumour volume doses when tumour and plaque characteristics were altered, including eccentric plaque placement, either away from (tilt) or along (offset) scleral surface, tumour shape, and plaque type., Results: D99% was always greater than the apex dose when plaques were placed centrally, and the difference increased with tumour thickness. Increasing degrees of tumour offset reduced apical dose and D99% , with a greater effect on apical dose for thicker and D99% for thinner tumours, respectively. Differences in tumour shape and plaque type had idiosyncratic effects on apical and volume dosing., Conclusion: D99% and apex dose are affected by tumour and treatment characteristics in different ways, highlighting the complexity of radiation delivery to uveal tumours., Competing Interests: Footnotes and Disclosure Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors Commercial relationships disclosures: Emeritus Professor M.A. Astrahan is the proprietary founder and owner of the Plaque Simulator(TM) software. Nil additional disclosures by any other author., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
8. Adaptive optics imaging in inherited retinal diseases: A scoping review of the clinical literature.
- Author
-
Britten-Jones AC, Thai L, Flanagan JPM, Bedggood PA, Edwards TL, Metha AB, and Ayton LN
- Subjects
- Humans, Retina diagnostic imaging, Retinal Cone Photoreceptor Cells, Ophthalmoscopy methods, ATP-Binding Cassette Transporters, Retinal Diseases diagnostic imaging, Retinal Diseases genetics, Usher Syndromes
- Abstract
Adaptive optics (AO) imaging enables direct, objective assessments of retinal cells. Applications of AO show great promise in advancing our understanding of the etiology of inherited retinal disease (IRDs) and discovering new imaging biomarkers. This scoping review systematically identifies and summarizes clinical studies evaluating AO imaging in IRDs. Ovid MEDLINE and EMBASE were searched on February 6, 2023. Studies describing AO imaging in monogenic IRDs were included. Study screening and data extraction were performed by 2 reviewers independently. This review presents (1) a broad overview of the dominant areas of research; (2) a summary of IRD characteristics revealed by AO imaging; and (3) a discussion of methodological considerations relating to AO imaging in IRDs. From 140 studies with AO outcomes, including 2 following subretinal gene therapy treatments, 75% included fewer than 10 participants with AO imaging data. Of 100 studies that included participants' genetic diagnoses, the most common IRD genes with AO outcomes are CNGA3, CNGB3, CHM, USH2A, and ABCA4. Confocal reflectance AO scanning laser ophthalmoscopy was the most reported imaging modality, followed by flood-illuminated AO and split-detector AO. The most common outcome was cone density, reported quantitatively in 56% of studies. Future research areas include guidelines to reduce variability in the reporting of AO methodology and a focus on functional AO techniques to guide the development of therapeutic interventions., Competing Interests: Declaration of Competing Interest ACBJ, LT, JPMF, PAB, and ABM have no financial disclosures. TLE has received consulting fees from Novartis Pharmaceuticals. LNA has received speaker honoraria from Apellis and Novartis Pharmaceuticals and holds intellectual property rights with Bionic Eye Technologies, USA. All these financial affiliations are outside of the submitted work. The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. A pilot study of the pharmacokinetics of continuous magnesium infusion in critically ill patients.
- Author
-
Chan JW, Yanase F, See E, McCue C, Yong ZT, Talbot LJ, Flanagan JPM, and Eastwood GM
- Abstract
Objective: The pharmacokinetics and haemodynamic effect of continuous magnesium infusion in non-cardiac intensive care unit (ICU) patients are poorly understood. We aimed to measure serum and urine magnesium levels during bolus and continuous infusion in critically ill adults, compare serum levels with those of a control population, and assess its haemodynamic effect. Design: Pharmacokinetic study Setting: A single tertiary adult ICU. Participants: Mechanically ventilated adults requiring vasopressor support. Intervention: A 10 mmol bolus of magnesium sulfate followed by 1.5-3 mmol/h infusion for 24 hours. Main outcome measures: The primary outcome was the change in total serum magnesium concentration. The main secondary outcome was mean arterial pressure (MAP)- adjusted vasopressor dose. Results: We matched 31 treated patients with 93 controls. Serum total magnesium concentration increased from a median 0.94 mmol/L (interquartile range [IQR], 0.83-1.10 mmol/L) to 1.38 mmol/L (IQR, 1.25-1.69 mmol/L; P < 0.001) and stabilised between a median 1.64 mmol/L (IQR, 1.38-1.88 mmol/L) at 7 hours and 1.77 mmol/L (IQR, 1.53-1.85 mmol/L) at 25 hours. This was significantly greater than in the control group ( P < 0.001). The MAP-adjusted vasopressor dose decreased during magnesium infusion ( P < 0.001). Conclusion: In critically ill patients, a magnesium sulfate bolus followed by continuous infusion achieved moderately elevated levels of total serum magnesium with a decrease in MAP-adjusted vasopressor dose. Trial registration number: ACTRN12619000925145., Competing Interests: All authors declare that they do not have any potential conflict of interest in relation to this manuscript., (© 2022 College of Intensive Care Medicine of Australia and New Zealand.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.